Get started
Author

María Rodríguez‐Remírez

Observed names: M Rodríguez-Remírez, M. Rodriguez-Remirez, M. Rodríguez-Remírez, Maria Rodriguez-Reminez, Maria Rodriguez-Remirez, María Rodriguez-Remirez, María Rodríguez-Remirez, María Rodríguez-Remírez, Rodriguez-Remirez, Maria, Rodríguez-Remírez, M.
Observed institutions: Hospital Clínico San Carlos, Navarre Institute of Health Research, Hospital Universitario Fundación Jiménez Díaz, Clinica Universidad de Navarra, Centro de Investigación Médica Aplicada, Instituto de Investigación Sanitaria Fundación Jiménez Díaz, Universidad Autónoma de Madrid, Universidad de Navarra
OpenAlex ID: A5028949281
Vitamin C uncouples the Warburg metabolic switch in KRAS mutant colon cancer
2016 · Oscar Aguilera, María Muñoz-Sagastibelza, et al. · Oncotarget · 84
UNR/ CSDE1 Expression Is Critical to Maintain Invasive Phenotype of Colorectal Cancer Through Regulation of c-MYC and Epithelial-to-Mesenchymal Transition
2019 · Javier Martinez-Useros, Nuria Garcia-Carbonero, et al. · Journal of Clinical Medicine · 34
PDF
Prognostic significance of neutrophil-to lymphocyte ratio and platelet-to lymphocyte ratio in older patients with metastatic colorectal cancer
2018 · Marlid Cruz-Ramos, Laura del Puerto-Nevado, et al. · Journal of Geriatric Oncology · 30
Active angiogenesis in metastatic renal cell carcinoma predicts clinical benefit to sunitinib-based therapy
2014 · L del Puerto-Nevado, F Rojo, et al. · British Journal of Cancer · 28
PDF
DEK is a potential marker for aggressive phenotype and irinotecan-based therapy response in metastatic colorectal cancer
2014 · Javier Martinez-Useros, Maria Rodriguez-Remirez, et al. · BMC Cancer · 25
PDF
Overcoming PLK1 inhibitor resistance by targeting mevalonate pathway to impair AXL-TWIST axis in colorectal cancer
2021 · Sonia Solanes-Casado, Arancha Cebrián, et al. · Biomedicine & Pharmacotherapy · 23
PDF
Trametinib sensitizes KRAS-mutant lung adenocarcinoma tumors to PD-1/PD-L1 axis blockade via Id1 downregulation
2024 · Ander Puyalto, María Rodríguez-Remírez, et al. · Molecular Cancer · 21
PDF
Signature-driven repurposing of Midostaurin for combination with MEK1/2 and KRASG12C inhibitors in lung cancer
2023 · Irati Macaya, Marta Roman, et al. · Nature Communications · 21
PDF
Focal adhesion kinase: predictor of tumour response and risk factor for recurrence after neoadjuvant chemoradiation in rectal cancer
2016 · Teresa Gómez del Pulgar, Arancha Cebrián, et al. · Journal of Cellular and Molecular Medicine · 21
PDF
Id1 and PD-1 Combined Blockade Impairs Tumor Growth and Survival of KRAS-mutant Lung Cancer by Stimulating PD-L1 Expression and Tumor Infiltrating CD8+ T Cells
2020 · Iosune Baraibar, Marta Roman, et al. · Cancers · 18
PDF
UNR/CDSE1 expression as prognosis biomarker in resectable pancreatic ductal adenocarcinoma patients: A proof-of-concept
2017 · Javier Martinez-Useros, Tihomir Georgiev-Hristov, et al. · PLoS ONE · 17
PDF
The potential predictive value of DEK expression for neoadjuvant chemoradiotherapy response in locally advanced rectal cancer
2018 · J. Martinez-Useros, I. Moreno, et al. · BMC Cancer · 15
PDF
Decreased PLK1 expression denotes therapy resistance and unfavourable disease-free survival in rectal cancer patients receiving neoadjuvant chemoradiotherapy
2016 · Arancha Cebrián, Teresa Gómez del Pulgar, et al. · Pathology - Research and Practice · 15
Predictive value of vrk 1 and 2 for rectal adenocarcinoma response to neoadjuvant chemoradiation therapy: a retrospective observational cohort study
2016 · Laura del Puerto-Nevado, Juan Pablo Marin-Arango, et al. · BMC Cancer · 14
PDF
967P The time of anti-PD-1 infusion improves survival outcomes by fasting conditions simulation in non-small cell lung cancer
2021 · A. Vilalta, H. Arasanz, et al. · Annals of Oncology · 13
PDF
Strong Antitumor Activity of Bevacizumab and Aflibercept in Neuroendocrine Carcinomas: In-Depth Preclinical Study
2019 · María Rodríguez-Remírez, Laura del Puerto-Nevado, et al. · Neuroendocrinology · 11
Combination of KIR2DS4 and FcγRIIa polymorphisms predicts the response to cetuximab in KRAS mutant metastatic colorectal cancer
2019 · A. Borrero-Palacios, A. Cebrián, et al. · Scientific Reports · 11
Functional PTGS2 polymorphism-based models as novel predictive markers in metastatic renal cell carcinoma patients receiving first-line sunitinib
2017 · Arancha Cebrián, Teresa Gómez del Pulgar, et al. · Scientific Reports · 9
Targeting Galectin-1 by Aflibercept Strongly Enhances Its Antitumor Effect in Neuroendocrine Carcinomas
2020 · María Rodríguez-Remírez, Laura del Puerto-Nevado, et al. · Neuroendocrinology · 7
A novel [89Zr]-anti-PD-1-PET-CT to assess response to PD-1/PD-L1 blockade in lung cancer
2023 · Ander Puyalto, María Rodríguez-Remírez, et al. · Frontiers in Immunology · 6
PDF
Identification of Poor-outcome Biliopancreatic Carcinoma Patients With Two-marker Signature Based on ATF6α and p-p38 “STARD Compliant”
2015 · J. Martinez-Useros, T. Georgiev-Hristov, et al. · Medicine · 6
Author Correction: Combination of KIR2DS4 and FcγRIIa polymorphisms predicts the response to cetuximab in KRAS mutant metastatic colorectal cancer
2019 · A. Borrero-Palacios, A. Cebrián, et al. · Scientific Reports · 2
PDF
P12.03 The Time of Anti-PD-1 Infusion Improves Survival Outcomes by Fasting Conditions Simulation in Non-Small Cell Lung Cancer
2021 · A. Vilalta-Lacarra, M. Rodriguez-Remirez, et al. · Journal of Thoracic Oncology · 1
P12.01 A Novel 89Zr-α-PD-1 Immuno-PET-CT May Improve Pseudoprogression Detection in a Lung Cancer Murine Model Receiving Immunotherapy
2021 · A. Puyalto, M. Rodriguez-Remirez, et al. · Journal of Thoracic Oncology · 1
PDF
P-041 IKAROS: a potential prognostic marker in pancreatic ductal adenocarcinoma
2016 · M. Cruz Ramos, M. Rodriguez-Remirez, et al. · Annals of Oncology · 1
PDF
Works count: 32
Citation count: 434
H-index: 14
I10-index: 17
Year
Topic
Type